Your session is about to expire
← Back to Search
Behavioural Intervention
VR Speech-Language Therapy for Speech Disorders
N/A
Recruiting
Led By Adriana Rios Rincon, PhD, R.OT
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Presence of a speech disorder
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 weeks
Awards & highlights
Study Summary
This trial aims to improve patient adherence to rehabilitation therapies by using virtual reality (VR) to make them more fun/engaging. It hopes to improve outcomes and satisfaction with vocal therapy.
Who is the study for?
This trial is for English-speaking adults with a speech disorder who are currently receiving speech-language therapy at the Glenrose Rehabilitation Hospital. They must be able to consent to participate. It's not for those with substance use disorders, comprehension issues due to communication disorders, severe cognitive or behavioral impairments, or a history of neurological or psychiatric conditions.Check my eligibility
What is being tested?
The study tests the effectiveness of Virtual Reality (VR) GlenXRose Speech-Language Therapies in improving patient adherence and treatment outcomes compared to traditional methods. It aims to make rehabilitation engaging through gamification and assesses feasibility, clinician feedback, costs, and clinical results.See study design
What are the potential side effects?
While specific side effects are not detailed for VR therapies, potential discomforts may include motion sickness from VR use, eye strain or fatigue from prolonged screen time. These experiences can vary among individuals.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a speech disorder.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Acoustic Analysis of Voice
Change in Compliance Rate
Change in Frequency and Treatment Adherence Rates
+2 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Virtual Reality Delivered Therapy + Standard Clinical CareExperimental Treatment1 Intervention
The GlenXRose virtual reality therapies will be delivered to participants using a head-mounted device to allow vocal therapy and practice. Participants will also receive routine clinical care provided by speech-language pathologists.
Group II: Standard Clinical CareActive Control1 Intervention
Participants will receive routine clinical care provided by speech-language pathologists.
Find a Location
Who is running the clinical trial?
University of AlbertaLead Sponsor
891 Previous Clinical Trials
385,627 Total Patients Enrolled
Alberta Health servicesOTHER
158 Previous Clinical Trials
649,636 Total Patients Enrolled
Antonio Miguel Cruz, DrScStudy ChairUniversity of Alberta
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am currently receiving speech-language therapy at Glenrose Rehabilitation Hospital.You have had a neurological or psychiatric disorder in the past.You have a problem with using drugs or alcohol.You have trouble understanding and following spoken instructions and using the scales in the study.You have significant problems with thinking or behavior.I have a speech disorder.
Research Study Groups:
This trial has the following groups:- Group 1: Virtual Reality Delivered Therapy + Standard Clinical Care
- Group 2: Standard Clinical Care
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is participation in this trial still viable for potential participants?
"According to the information available on clinicaltrials.gov, no new patients are currently being recruited for this trial which was initially posted on April 1st 2023 and last updated January 14th of the same year. Nevertheless, there are 8 different medical studies that presently require enrolment at this time."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger